Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

[CUHK Medical Grand Rounds] Cases of hemichorea-hemiballism with similar clinical presentations but different underlying aetiologies

Dr. Lisa WC Au
Division of Neurology
Department of Medicine & Therapeutics
Chinese University of Hong Kong
01 Feb 2019

CU_banner_2017

Introduction

Ballism is a hyperkinetic movement disorder characterized by involuntary, irregular, dramatic, large-amplitude flinging movements involving proximal muscles. It is derived from a Greek word meaning “to throw”. When one side of the body is involved, the condition is termed hemiballism. Often, ballism evolves into more distal and lower-amplitude movements, which are referred to as chorea. There is considerable overlap in the appearances of ballism and chorea. Ballistic and choreiform movements may coexist in many patients, and it is not uncommon for ballism to evolve into a more distal and lower-amplitude chorea. Thus, chorea and ballism are viewed as part of a clinical spectrum of the same pathophysiological process, and consequently the term “hemichorea-hemiballism” (HC-HB) is frequently used in the literature. In traditional teaching, it is pathognomonic of a lesion in the contralateral subthalamic nucleus (STN). In this article, we present two cases with similar clinical presentations due to different underlying aetiologies.

Case 1

A 73-year-old man with good past health presented to the emergency department with a few days’ history of involuntary low-amplitude unpredictable movements of his left arms and legs. He did not have any motor weakness, sensory changes, and visual or speech disturbances. He was a chronic smoker and had no family history of neurologic diseases. Physical examination was notable for left hemichorea. His sensorium was normal and he had full limb power. Blood tests showed normal biochemistry results. Fasting blood glucose was 5.4 mmol/L and LDL-cholesterol was 3.5 mmol/L. MRI brain revealed a small restricted diffusion focus over the right high frontoparietal lobe, compatible with an early subacute infarct. (Figure 1) His involuntary movements subsided gradually over a day and he was started on aspirin for secondary prophylaxis of stroke.

MD Feb 2019 CASE STUDY Figure 1

 

Case 2

An 84-year-old man with a few years’ history of type 2 diabetes mellitus was admitted with 2 days’ history of involuntary flinging movements of his right arm and leg. These movements were not suppressible and interfered with sleep and activity. He had defaulted follow-up for his diabetes for a month before admission. Same as the previous case, this patient had no other neurological deficits on examination apart from hemiballism. Blood tests showed high blood glucose (18 mmol/L) and HbA1c (13.7 percent) with no acidosis. Plain CT brain showed hyperdensity over the left basal ganglia. (Figure 2) MRI brain demonstrated T1-hyperintense and T2-hypointense left caudate and lentiform nuclei. (Figure 3) There was no discrete focus of restricted diffusion to suggest acute infarction. He was started on an oral hypoglycaemic agent and a short course of tetrabenazine. His involuntary movements subsided gradually over a few weeks.

MD Feb 2019 CASE STUDY Figure 2
MD Feb 2019 CASE STUDY Figure 3

 

Discussion

HC-HB is a movement disorder typically characterized by rapid involuntary jerky movements and periodic uncoordinated swings involving a unilateral limb, as manifesting in our patients. Traditionally, its emergence points to a structural lesion or metabolic dysfunction in the region of the STN on the side contralateral to the movements.1

Stroke represents up to 22 percent of secondary movement disorders, and involuntary movements develop after 1–4 percent of stroke cases.2 Post-stroke movement disorders can manifest in a wide range of hyperkinetic movement disorders, including HC-HB, dystonia, tremor, myoclonus and athetosis. HC-HB is the most common movement disorder following stroke.3 Although the classical location of lesions causing hemiballism is the STN, lesions affecting various areas, such as striatum, thalamus, globus pallidus and cortex, are also possible causes, with lesions of the contralateral striatum being the commonest cause.4 It has been reported that transient ischaemic attacks (TIAs) secondary to middle cerebral artery (MCA) stenosis can present as recurrent episodes of HC-HB.5

Another important condition to be distinguished from stroke-induced HC-HB is hyperglycaemia-related HC-HB. It occurs in the setting of severe nonketotic hyperglycaemia (NKH) in the elderly and shows characteristic radiological finding. This condition was first described in 1960.6 Since then, multiple case reports and case series from different ethnic backgrounds have been published, with a majority of cases occurring in patients of Asian descent.7 The characteristic radiological finding is a high signal intensity basal ganglia lesion on T1-weighted brain MRI.8 Hence, the term “C-H-BG” has been coined for the hallmarks of chorea, hyperglycaemia and basal ganglia changes on MRI. The precise mechanism is unknown. Petechial haemorrhage in the putamen resulting from compromise of the blood-brain barrier is a leading hypothesis for this condition.9 It is important for clinicians to recognize C-H-BG as one of the rare and reversible complications of poorly controlled diabetes mellitus to ensure early diagnosis and management.

The treatment of HC-HB depends on the underlying aetiology. For hyperglycaemia-related HC-HB, normalization of blood glucose is the mainstay of treatment and often leads to complete resolution of symptoms. Treatment options for persistent HC-HB despite blood glucose control include neuroleptics, tetrabenazine and medications with GABAergic properties, including benzodiazepines. Tetrabenazine is a vesicular monoamine transporter inhibitor depleting dopamine and other central monoamines. It is used to treat chorea and other hyperkinetic movement disorders. For patients on tetrabenazine, clinicians should monitor possible adverse reactions such as Parkinsonism and depression/suicidality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.